Biotech | January 10, 2022
Novavax and Serum file EUA for Covovax in South Africa
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
The transaction is expected to close in the first quarter of 2022
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
Biogen paid Ionis a US $ 60 million one-time upfront payment
It has also been granted permission to conduct trials for booster dose
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
Subscribe To Our Newsletter & Stay Updated
